Market-View-Feature-Image

View on market: Stay Cautious, be with quality business:

Stocks in Asia were steady Friday as investors weighed the resilience of the global economic recovery to risks from tightening of U.S. Federal Reserve’s monetary policy and Russia’s military campaign in Ukraine. Singapore-traded SGX Nifty, an early barometer of India’s benchmark Nifty 50 index, fell 0.23% to 17,263.2 points as of 7:00 am. Japanese, Australian and South Korean equities fluctuated in relatively narrow ranges. U.S. futures slipped after technology stocks helped the S&P 500 index to close at a more than six-week high. Treasuries pared some of the declines they posted Thursday. The U.S. 10-year yield was still in the vicinity of levels last seen in 2019. Oil retreated, though West Texas Intermediate crude remained above $110/barrel.

Economic Calendar:

  • INR: Forex Reserve on 25th March 2022.
  • INR: Forex Reserve on 1st April 2022.
  • USD: Retail Inventory Ex Auto 28th March, 2022.
  • USD: Wholesale Inventory on 28th March, 2022.

Brokerage Radar:

UBS ON ZEE ENTERTAINMENT: Neutral, TP Rs 315 Invesco announces withdrawal of EGM requisition This was a major overhang on proposed merger with Sony Withdrawal of requisition by Invesco, therefore, is a positive for Zee.

JP MORGAN ON TITAN: Neutral, TP Rs 2618 Unattractive risk reward in short term: Navigating gold price volatility & wallet share shifts Our store channel checks suggest a tapering of demand in recent weeks with increased gold price volatility & more alternatives for discretionary spends, With valuations at 77x/64x FY23/24E P/E & limited scope for EPS upgrades, share price returns could be modest in short term.

CLSA ON UPL: Buy, TP Rs 1100 Rising soft commodity prices due to ongoing geopolitical tensions, higher demand for UPL’s Glufosinate as a key competitor faces supply issues, & benefits of price increases taken last yr bode well co’s rev & profitability.

CLSA ON MARUTI: Sell, TP cut 6430 Spike in commodity costs & loss in market share are major challenges Believe street is too optimistic on volume & margin recovery Expect MSIL to lose 480bps market share over FY21-24 Have cut FY23CL earnings by 20%

International Markets:

U.S & Europe:

Particulars 24th Mar Chg Chg(%)
Nasdaq 14,191.84 269.24 1.93
Dow 34707.94 349.44 1.02
FTSE 7,467.38 6.75 0.09
CAC 6,555.77 -25.66 -0.39
DAX 14,273.79 -9.86 -0.07
Dow Fut.* 34755.6 46.7 0.14

Asian markets:

Particulars 25th  Mar Chg. Chg(%)
SGX Nifty 17,278.00 56 0.33
Nikkei 28,062.18 -48.21 -0.17
Straits Times 3,416.82 17.12 0.5
Hang Seng 21,836.06 -109.89 -0.5
Shanghai 3,249.18 -1.08 -0.03

ADR Watch:

Particulars 24th Mar Chg. Chg.(%)
Dr Reddy 56.22 3 5.64
HDFC Bank 60.8 0.41 0.68
ICICI Bank 18.26 0.15 0.83
Infosys 24.67 0.36 1.48
Tata Motor 28.58 0.43 1.53
Wipro 7.93 0.08 1.02

Commodities & Currency:

Particulars Current Price Chg(%)
USD/INR 76.36 0.09
Brent 119 0.16
Gold 1962.00 -0.02
Silver 25.977 0.20

FIIs & DII:

Particulars 24th Mar 23rd Mar
FIIs -1740.71 481.3
DIIs 2091.07 -294.23

News Update:

Tata Consumer: The company will consider preferential issue of equity shares representing 1.5% of the paid-up share capital to a foreign company on March 29.

Punjab and Sind Bank: The bank will consider approval for the exercise of the Call Option on the Additional Tier I Bond Series on March 29.

Gulshan Polyols: The company approved allotment of 24,16,000 equity shares to five QIBs at the issue price of Rs 326.48 per share (including a premium of 325.48 at the face value of Rs 1 per share) which is at a discount of 5% to the floor price of Rs 343.66 per share.

Axis Bank: SEBI levied a penalty of Rs 5 lakh on the bank for violation of debt issuance norms. The matter related to issue of debt securities between 2016 and 2019, where the bank acted as a merchant banker.

Zen Technology: The company received a project order sanction from the Indian Army for design and development of a prototype of the Integrated Air Defence Combat Simulator. The equipment will help in imparting training to gunners at unit level.
Future Enterprises: The company couldn’t pay Rs 93.99 crore to Punjab National Bank and Canara Bank under one-time resolution plan.

Yes Bank: The bank will consider redemption/interest payment date of bonds on April 12.

Lupin: The company has received approval from the United States Food and Drug Administration for Sildenafil for oral suspension, 10 mg/ml to market a generic equivalent of Revatio for oral suspension. The drug will be manufactured at company’s facility in Goa.

NTPC: The company commissioned 42.5 MW of 100 MW Ramagundam Floating Solar PV Project in Telangana, taking the company’s total commercial capacity to 54,494.68 MW.

Union Bank/Bank of Baroda: The bank reduced its stake in National Asset Reconstruction company from 13.27% to 9.9%.

PNB Housing: The company entered strategic co-lending agreement with State Bank of India to offer retail loans to homebuyers. The two financial institutions will co-originate loans at an agreed ratio of 20:80 interest rates.

Source: Moneycontrol, Livemint,, Bloomberg, Investing 

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL